Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) Income from Continuing Operations: 2012-2023

Historic Income from Continuing Operations for RedHill Biopharma (RDHL) over the last 11 years, with Jun 2023 value amounting to $58.9 million.

  • RedHill Biopharma's Income from Continuing Operations rose 231.03% to $58.9 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$40.0 million, marking a year-over-year increase of 75.62%. This contributed to the annual value of -$8.3 million for FY2024, which is 134.57% down from last year.
  • According to the latest figures from Q2 2023, RedHill Biopharma's Income from Continuing Operations is $58.9 million, which was up 844.05% from -$7.9 million recorded in Q1 2023.
  • RedHill Biopharma's Income from Continuing Operations' 5-year high stood at $58.9 million during Q2 2023, with a 5-year trough of -$145.2 million in Q4 2021.
  • Moreover, its 3-year median value for Income from Continuing Operations was $2.4 million (2022), whereas its average is -$17.0 million.
  • As far as peak fluctuations go, RedHill Biopharma's Income from Continuing Operations skyrocketed by 232.46% in 2020, and later tumbled by 469.08% in 2021.
  • Over the past 5 years, RedHill Biopharma's Income from Continuing Operations (Quarterly) stood at $11.8 million in 2019, then skyrocketed by 232.46% to $39.4 million in 2020, then plummeted by 469.08% to -$145.2 million in 2021, then skyrocketed by 52.14% to -$69.5 million in 2022, then surged by 231.03% to $58.9 million in 2023.
  • Its last three reported values are $58.9 million in Q2 2023, -$7.9 million for Q1 2023, and -$69.5 million during Q4 2022.